Answers are grounded in this paper and cite their sources.
Smaller amounts of proteins are now required to screen for weak binding interactions between ligands and the active site of metalloproteins as a result of the substitution of diamagnetic zinc(II) with paramagnetic cobalt(II) in the matrix metalloproteinase MMP-12. 1H NMR spectroscopy then provides qualitative information on the orientation of the ligand in the catalytic site targeted by drugs (see picture).
No takes yet. Share an insight, caveat, or question.
Bertini et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: